全文获取类型
收费全文 | 56586篇 |
免费 | 17524篇 |
国内免费 | 3314篇 |
出版年
2024年 | 63篇 |
2023年 | 334篇 |
2022年 | 771篇 |
2021年 | 1620篇 |
2020年 | 2999篇 |
2019年 | 4759篇 |
2018年 | 4800篇 |
2017年 | 4881篇 |
2016年 | 5255篇 |
2015年 | 5785篇 |
2014年 | 5911篇 |
2013年 | 6391篇 |
2012年 | 4800篇 |
2011年 | 4276篇 |
2010年 | 4769篇 |
2009年 | 3316篇 |
2008年 | 2721篇 |
2007年 | 2167篇 |
2006年 | 1902篇 |
2005年 | 1770篇 |
2004年 | 1571篇 |
2003年 | 1457篇 |
2002年 | 1303篇 |
2001年 | 784篇 |
2000年 | 629篇 |
1999年 | 524篇 |
1998年 | 320篇 |
1997年 | 240篇 |
1996年 | 174篇 |
1995年 | 137篇 |
1994年 | 126篇 |
1993年 | 78篇 |
1992年 | 113篇 |
1991年 | 87篇 |
1990年 | 78篇 |
1989年 | 64篇 |
1988年 | 63篇 |
1987年 | 36篇 |
1986年 | 38篇 |
1985年 | 34篇 |
1984年 | 30篇 |
1983年 | 27篇 |
1982年 | 25篇 |
1981年 | 24篇 |
1980年 | 14篇 |
1979年 | 18篇 |
1978年 | 13篇 |
1976年 | 11篇 |
1975年 | 11篇 |
1972年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
991.
Yuyu Li Yuxin Zhang Jianrong Lu Yong Yin Jun Xie Biao Xu 《Journal of cellular and molecular medicine》2021,25(17):8087-8094
Inflammatory responses play a vital role in the onset and development of atherosclerosis, and throughout the entire process of the chronic disease. The inflammatory responses in atherosclerosis are mainly mediated by the NLRP3 inflammasome and its downstream inflammatory factors. As a powerful anti-inflammatory medicine, colchicine has a history of more than 200 years in clinical application and is the first-choice treatment for immune diseases such as gout and familial Mediterranean fever. In atherosclerosis, colchicine can inhibit the assembly and activation of NLRP3 inflammasome via various mechanisms to effectively reduce the expression of inflammatory factors, thereby reducing the inflammation. Recent clinical trials show that a low dose of colchicine (0.5 mg per day) has a certain protective effect in stable angina patients or those with acute myocardial infarction after PCI. This article summarizes and discusses the mechanisms of colchicine in the treatment of atherosclerosis and the latest research progress. 相似文献
992.
993.
Jang Hye Jin Choi Ji Yeon Kim Kangjoon Yong Seung Hyun Kim Yeon Wook Kim Song Yee Kim Eun Young Jung Ji Ye Kang Young Ae Park Moo Suk Kim Young Sam Cho Young-Jae Lee Sang Hoon 《Respiratory research》2021,22(1):1-9
IL-35 subunit EBI3 is up-regulated in pulmonary fibrosis tissues. In this study, we investigated the pathological role of EBI3 in pulmonary fibrosis and dissected the underlying molecular mechanism. Bleomycin-induced pulmonary fibrosis mouse model was established, and samples were performed gene expression analyses through RNAseq, qRT-PCR and Western blot. Wild type and EBI3 knockout mice were exposed to bleomycin to investigate the pathological role of IL-35, via lung function and gene expression analyses. Primary lung epithelial cells were used to dissect the regulatory mechanism of EBI3 on STAT1/STAT4 and STAT3. IL-35 was elevated in both human and mouse with pulmonary fibrosis. EBI3 knockdown aggravated the symptoms of pulmonary fibrosis in mice. EBI3 deficiency enhanced the expressions of fibrotic and extracellular matrix-associated genes. Mechanistically, IL-35 activated STAT1 and STAT4, which in turn suppressed DNA enrichment of STAT3 and inhibited the fibrosis process. IL-35 might be one of the potential therapeutic targets for bleomycin-induced pulmonary fibrosis. 相似文献
994.
Mario Gimona Maria Felice Brizzi Andre Boon Hwa Choo Massimo Dominici Sean M. Davidson Johannes Grillari Dirk M. Hermann Andrew F. Hill Dominique de Kleijn Ruenn Chai Lai Charles P. Lai Rebecca Lim Marta Monguió-Tortajada Maurizio Muraca Takahiro Ochiya Luis A. Ortiz Wei Seong Toh Yong Weon Yi Sai Kiang Lim 《Cytotherapy》2021,23(5):373-380
Mesenchymal stromal/stem cells (MSCs) have been widely tested against many diseases, with more than 1000 registered clinical trials worldwide. Despite many setbacks, MSCs have been approved for the treatment of graft-versus-host disease and Crohn disease. However, it is increasingly clear that MSCs exert their therapeutic functions in a paracrine manner through the secretion of small extracellular vesicles (sEVs) of 50–200 nm in diameter. Unlike living cells that can persist long-term, sEVs are non-living and non-replicative and have a transient presence in the body. Their small size also renders sEV preparations highly amenable to sterilization by filtration. Together, acellular MSC-sEV preparations are potentially safer and easier to translate into the clinic than cellular MSC products. Nevertheless, there are inherent challenges in the development of MSC-sEV drug products. MSC-sEVs are products of living cells, and living cells are sensitive to changes in the external microenvironment. Consequently, quality control metrics to measure key identity and potency features of MSC-sEV preparations have to be specified during development of MSC-sEV therapeutics. The authors have previously described quantifiable assays to define the identity of MSC-sEVs. Here the authors discuss requirements for prospective potency assays to predict the therapeutic effectiveness of the drug substance in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Although potency assays should ideally reflect the mechanism of action (MoA), this is challenging because the MoA for the reported efficacy of MSC-sEV preparations against multiple diseases of diverse underlying pathology is likely to be complex and different for each disease and difficult to fully elucidate. Nevertheless, robust potency assays could be developed by identifying the EV attribute most relevant to the intended biological activity in EV-mediated therapy and quantifying the EV attribute. Specifically, the authors highlight challenges and mitigation measures to enhance the manufacture of consistent and reproducibly potent sEV preparations, to identify and select the appropriate EV attribute for potency assays despite a complex “work-in-progress” MoA and to develop assays likely to be compliant with regulatory guidance for assay validation. 相似文献
995.
Sanna Loppi Paula Korhonen Maria Bouvy‐Liivrand Simone Caligola Tiia A. Turunen Mikko P. Turunen Ana Hernandez de Sande Natalia Koosowska Flavia Scoyni Anna Rosell Teresa García‐Berrocoso Sighild Lemarchant Hiramani Dhungana Joan Montaner Jari Koistinaho Katja M. Kanninen Minna U. Kaikkonen Rosalba Giugno Merja Heinniemi Tarja Malm 《Aging cell》2021,20(1)
996.
997.
998.
Pak Valeriy V. Kwon Dae Yong Khojimatov Olim K. Pak Aleksandr V. Sagdullaev Shomansur Sh. 《International journal of peptide research and therapeutics》2021,27(3):1923-1931
International Journal of Peptide Research and Therapeutics - This study presents a simple approach in design of tripeptides as a competitive inhibitor for 3-hydroxy-3-methylglutaryl CoA reductase... 相似文献
999.
1000.
Jing Cui Kai Shan Qin Yang Yumin Qi Hongyan Qu Jiaqi Li Rong Wang Lingling Jia Wei Chen Ninghan Feng Yong Q. Chen 《Journal of cellular and molecular medicine》2021,25(12):5586-5601
Alternative polarization of macrophages regulates multiple biological processes. While M1-polarized macrophages generally mediate rapid immune responses, M2-polarized macrophages induce chronic and mild immune responses. In either case, polyunsaturated fatty acid (PUFA)-derived lipid mediators act as both products and regulators of macrophages. Prostaglandin E3 (PGE3) is an eicosanoid derived from eicosapentaenoic acid, which is converted by cyclooxygenase, followed by prostaglandin E synthase successively. We found that PGE3 played an anti-inflammatory role by inhibiting LPS and interferon-γ-induced M1 polarization and promoting interleukin-4-mediated M2 polarization (M2a). Further, we found that although PGE3 had no direct effect on the growth of prostate cancer cells in vitro, PGE3 could inhibit prostate cancer in vivo in a nude mouse model of neoplasia. Notably, we found that PGE3 significantly inhibited prostate cancer cell growth in a cancer cell-macrophage co-culture system. Experimental results showed that PGE3 inhibited the polarization of tumour-associated M2 macrophages (TAM), consequently producing indirect anti-tumour activity. Mechanistically, we identified that PGE3 regulated the expression and activation of protein kinase A, which is critical for macrophage polarization. In summary, this study indicates that PGE3 can selectively promote M2a polarization, while inhibiting M1 and TAM polarization, thus exerting an anti-inflammatory effect and anti-tumour effect in prostate cancer. 相似文献